Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Clin Pharmacol Ther. 2017 Nov 28;103(2):233–242. doi: 10.1002/cpt.903

Figure 2.

Figure 2

The allele frequencies for the reduced-function ABCG2 c.421C>A (BCRP Q141K) variant are shown for world populations (actual percentages in Supplemental Table S2) (15). This variant is common among Hispanic, Asian, and Caucasian populations and could cause complications in the administration of BCRP substrates and inhibitors, which are numerous. For example, there are 42 compounds that interact with BCRP on the World Health Organization List of Essential Medicines, listed here. An asterisk (*) indicates substrates for which BCRP activity has been shown to significantly affect pharmacokinetics in vivo. Sources for each medication can be found in Supplemental Table S4.